Valuation: Novacyt

Market Cap 33.19M 37.98M 30.62M 28.23M 53.2M 3.66B 54.39M 366M 144M 1.79B 143M 139M 6.17B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 35.14M 40.21M 32.43M 29.89M 56.34M 3.87B 57.59M 388M 152M 1.9B 151M 148M 6.53B EV / Sales 2026 *
1.15x
EV / Sales 2027 * 1.09x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.43%
1 week+13.23%
Current month+16.10%
1 month+12.25%
3 months+22.46%
6 months+16.39%
Current year+17.14%
1 week 0.4
Extreme 0.403
0.48
1 month 0.38
Extreme 0.3765
0.52
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap.
30/03/26 Buy

Chief Executive Officer

56,438 0.0799%
30/03/26 Buy

Chairman

15,228 0.0216%
30/03/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%+13.23%-3.17%-13.42% 37.98M
-2.93%+4.62%-36.01%-43.42% 640M
-9.12%+31.92%+179.80% - 515M
-4.31%-7.63%-41.84%+21.16% 114M
0.00%-5.08%+17.15%+70.73% 108M
Average -3.36%+7.41%+23.19%+8.76% 282.92M
Weighted average by Cap. -5.00%+13.06%+46.97%-20.33%

Financials

2026 *2027 *
Net sales 30.52M 34.93M 28.17M 25.96M 48.94M 3.36B 50.02M 337M 132M 1.65B 131M 128M 5.67B 34.86M 39.89M 32.17M 29.65M 55.89M 3.84B 57.13M 384M 151M 1.88B 150M 147M 6.48B
Net income - -
Net Debt 1.96M 2.24M 1.8M 1.66M 3.14M 216M 3.21M 21.57M 8.49M 106M 8.41M 8.22M 363M 4.84M 5.54M 4.47M 4.12M 7.76M 534M 7.93M 53.4M 21.01M 261M 20.81M 20.35M 900M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
17/07/26 €0.4580 -0.43% 294,137
16/07/26 €0.4600 +9.39% 289,717
15/07/26 €0.4205 +0.48% 425,005
14/07/26 €0.4185 +2.20% 192,433
13/07/26 €0.4095 +1.24% 38,099

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock